Tamatinib, also known as R406, is a potent inhibitor of immunoglobulin E (IgE)- and IgG-mediated activation of Fc receptor signaling (EC(50) for degranulation = 56-64 nM). The primary target for R406 is the spleen tyrosine kinase (Syk). R406 inhibited phosphorylation of Syk substrate linker for activation of T cells in mast cells and B-cell linker protein/SLP65 in B cells. R406 bound to the ATP binding pocket of Syk and inhibited its kinase activity as an ATP-competitive inhibitor (K(i) = 30 nM).
FLT3 Inhibitors Related Products:
Crenolanib; Dovitinib; FLX925; Quizartinib; Brigatinib; Pacritinib; Fedratinib; TG101209; SGI-1776; Tandutinib; SU5614; G-749